[ad_1] Ascendis Pharma European Commission decision for TransCon™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024 TransCon PTH NDA resubmission to FDA…
Tag: Ascendis
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
[ad_1] Ascendis Pharma • Third Quarter financial results and business update conference call to be held onNovember 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected…
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 | BioSpace
[ad_1] — Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon…
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
[ad_1] – Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023…
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
[ad_1] Ascendis Pharma COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business…
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
[ad_1] Ascendis Pharma Opens Compassionate Use Program for … Kentucky Today [ad_2] Source link
Recon: FDA declines to approve Ascendis’ hypoparathyroidism drug; Astellas to buy Iveric for $5.9B
[ad_1] Recon | 01 May 2023 | By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US FDA advisory committee votes against plan…
Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27
[ad_1] Ascendis Pharma COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on…
Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
[ad_1] Ascendis Pharma COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive…